Figure 1.

A: Histologic and fibrosis improvement with long-term entecavir treatment. Adapted from Chang et al.³ B: Proportions of hepatitis B virus (HBV) e-antigen-seronegative patients with reduction in HBV DNA to undetectable levels. Trials are not head-to-head comparisons and were conducted in different patient populations using different trial designs. Adapted from Lok et al, Marcellin et al, Baqai et al, Marcellin et al, Lau et al, Lim et al, Chang et al, Marcellin et al.^{4,5,7–11,21}